Using an aggressive mouse model of ovarian cancer, Ozmadenci et al. tested pharmacological FAK inhibition and observed a decrease in tumor burden and CD155 levels, as well as an increase in tumor-infiltrating lymphocytes. This evidence concerns the gene PVR and neoplasm.